A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitisinone (Primary)
Indications Tyrosinaemia type I
Focus Adverse reactions
Acronyms OPAL
Sponsors Swedish Orphan Biovitrum

Most Recent Events

22 Oct 2019 Status changed from recruiting to completed.
24 Jun 2018 Planned number of patients changed from 400 to 300.
29 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight